The Filing Desk

Arbutus Biopharma vs Taysha Gene Therapies

Arbutus Biopharma ABUS · Taysha Gene Therapies TSHA · Biotechnology

Arbutus Biopharma reported revenue of $14 million in fiscal 2025, 1.4 times Taysha Gene Therapies' $10 million in fiscal 2025. Arbutus Biopharma's revenue grew 128.2% in its latest year, and Taysha Gene Therapies' grew 17.3%. Arbutus Biopharma had an operating margin of -271.0%, against -1130.7% at Taysha Gene Therapies. Free cash flow was −$40 million at Arbutus Biopharma and −$94 million at Taysha Gene Therapies.

Side by side

Arbutus BiopharmaTaysha Gene Therapies
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$14M$10M
Revenue growth128.2%17.3%
Revenue growth a year, last 5 years15.4%—
Gross margin——
Operating margin−271.0%−1,130.7%
Net margin−237.9%−1,115.3%
Free cash flow−$40M−$94M
Free cash flow margin−281.4%−960.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.2%27.8%
Last close$4.09$4.10
P/E at the last close3.6×—
Insider trades, last 12 months——
Piotroski F-score3 of 84 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arbutus BiopharmaTaysha Gene Therapies
Operating margin
Percent of revenue
Arbutus BiopharmaTaysha Gene Therapies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arbutus BiopharmaTaysha Gene Therapies

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arbutus Biopharma and Taysha Gene Therapies pages.